Agenus Reports Landmark 3-Year OS Data for BOT+BAL in Refractory MSS mCRC at ESMO GI
Prostate Cancer: New ESTRO Recommendations for Precision Radiotherapy
Monica Bertagnolli: Don't Abolish the NIH, Fix It
BOT/BAL Shows 33% 3-Year OS in Refractory MSS mCRC Without Active Liver Metastases
Felicia Marie Knaul: WHO to Present First Global Estimates of 5-Year Breast Cancer Survival
Can SABR Replace Surgery in Selected Low-Risk Breast Cancer?
ESTRO Sets Practical Guidance for Focal Boosting in Prostate Cancer Radiotherapy 2026
Daraxonrasib for Pancreatic Cancer: What’s Next?
The ALRCaN Global webinar, “Managing Early T-Cell Precursor ALL: A Case-Based Discussion,” is scheduled for Friday, July 10, 2026, from 09:00 AM to 10:00 AM ET. Presented by Dr. Lisa Hartman and Dr. David Teachey, this case-based session will focus on the management of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL), highlighting clinical decision-making and […]
